> In clinical trials, XGEVA has been administered in combination with standard anti -cancer treatment and in subjects previously receiving BISPHOSPHONATES. There were no clinically -relevant alterations in trough serum concentration and pharmacodynamics of denosumab (creatinine adjusted urinary N-telopeptide, u
> NTX/Cr) by concomitant chemotherapy and/or hormone therapy or by previous intravenous BISPHOSPHONATE exposure. 
